Who are Sputnik Light's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b7 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Monovalent (OMI BA.4/BA.5), Famtozinameran 5 to 11 Years of age, BNT162b2 Bivalent (WT/OMI BA.1), MVC-COV1901(3 Months), BNT162b5 Bivalent (WT/OMI BA.2).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sputnik-light.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sputnik Light — Competitive Intelligence Brief

Sputnik Light (Sputnik Light) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Sputnik Light (Sputnik Light) — Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation. Sputnik Light is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sputnik Light TARGET	Sputnik Light	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)	bnt162b7-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
MVC-COV1901(3 Months)	MVC-COV1901(3 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
BNT162b5 Bivalent (WT/OMI BA.2)	bnt162b5-bivalent-wt-omi-ba-2	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

Janssen Vaccines & Prevention B.V. · 5 drugs in this class
University of Oxford · 3 drugs in this class
Crucell Holland BV · 3 drugs in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
Bharat Biotech International Limited · 2 drugs in this class
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Samia Hassan El-Shishtawy · 1 drug in this class
University Medicine Greifswald · 1 drug in this class
Aeras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sputnik Light — Competitive Intelligence Brief. https://druglandscape.com/ci/sputnik-light. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab